FdaApplication
NDA 208090
Identifiers
- fda_app_no: NDA208090
Properties
| Property | Value |
|---|---|
| applicant_name | COLLEGIUM PHARMACEUTICAL INC |
| application_type | NDA |
| approval_date | 2016-04-26 |
Revenue by product
XTAMPZA ER
| Period | Revenue |
|---|---|
| Q2 2026 | $45.0M |
| Q1 2026 | $50.8M |
| Q3 2025 | $50.5M |
| Q2 2025 | $105.2M |
| Q1 2025 | $95.3M |
| Q4 2024 | $51.5M |
| Q3 2024 | $49.5M |
| Q2 2024 | $44.6M |
| Q1 2024 | $45.8M |
| Q4 2023 | $48.5M |
| Q3 2023 | $39.8M |
| Q2 2023 | $41.2M |
| Q1 2023 | $47.9M |
| Q4 2022 | $35.2M |
| Q3 2022 | $38.9M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (5)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| XTAMPZA ER | OXYCODONE | 27MG | CAPSULE, EXTENDED RELEASE;ORAL |
| XTAMPZA ER | OXYCODONE | 13.5MG | CAPSULE, EXTENDED RELEASE;ORAL |
| XTAMPZA ER | OXYCODONE | 9MG | CAPSULE, EXTENDED RELEASE;ORAL |
| XTAMPZA ER | OXYCODONE | 36MG | CAPSULE, EXTENDED RELEASE;ORAL |
| XTAMPZA ER | OXYCODONE | 18MG | CAPSULE, EXTENDED RELEASE;ORAL |
5 products